Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Pepgen discontinues development of Duchenne MD exon-skipping therapy

Summary by Muscular Dystrophy News
Pepgen will stop development of its Duchenne MD exon-skipping therapy PGN-ED051 after increases in dystrophin levels proved disappointing.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Muscular Dystrophy NewsMuscular Dystrophy News

Pepgen discontinues development of Duchenne MD exon-skipping therapy

Pepgen will stop development of its Duchenne MD exon-skipping therapy PGN-ED051 after increases in dystrophin levels proved disappointing.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Muscular Dystrophy News broke the news on Tuesday, June 3, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Mississippi icon

Mississippi

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal